Search results
Results from the WOW.Com Content Network
By Sriparna Roy (Reuters) -The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's ...
Dupilumab. Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis. [6][7][8][4] It is also used for the treatment of eosinophilic esophagitis [9] and prurigo nodularis.
94558-4, 95209-3, 96119-3, 97097-0. COVID-19 rapid antigen tests or RAT s, also frequently called COVID-19 lateral flow tests or LFT s, are rapid antigen tests used to detect SARS-CoV-2 infection (COVID-19). They are quick to implement with minimal training, cost a fraction of other forms of COVID-19 testing, and give users a result within 5 ...
COVID-19 rapid antigen tests are lateral flow immunoassays that detect the presence of a specific viral antigen, which indicates current viral infection. Antigen tests produce results quickly (within approximately 15–30 minutes), and most can be used at the point-of-care or as self-tests.
Here’s a refresher on how and when to test for Covid, and what your at-home results really mean. Do rapid tests work on the variants in circulation? The short answer is yes.
The treatment and management of COVID-19 combines both supportive care, which includes treatment to relieve symptoms, fluid therapy, oxygen support as needed, [1][2][3] and a growing list of approved medications. Highly effective vaccines have reduced mortality related to SARS-CoV-2; however, for those awaiting vaccination, as well as for the ...
The most common include the Abbott BinaxNOW Self Test, the Quidel QuickVue At-Home OTC COVID-19 Test and the Ellume COVID-19 Home Test. Accuracy varies among each test, but Ellume says that its ...
The approval is based on results from the landmark phase 3 BOREAS and NOTUS studies, which were separately published in The New England Journal of Medicine and evaluated the efficacy and safety of Dupixent in adults with uncontrolled COPD with evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL). All patients were on ...